Fluxome Sciences, a Danish biotech company specialising in bio-based production of chemical compounds, will this month start selling its nutraceutical product resveratrol to dietary supplement manufacturers in the USA, reports financial daily newspaper Børsen.
Resveratrol is found in red wine and the skins of the grapes from which red wine is made. Scientific studies indicate that resveratrol possesses health-promoting properties that could explain the claimed health benefits associated with drinking moderate quantities of red wine.
Fluxome Sciences forecasts sales of up to USD 1m by April next year. Steen Andersen, MD of the company says: "The year after we expect exponential sales with a five to ten-fold increase in revenues compared to the first year, and we also expect to be in a segment where the market for this product as a minimum will grow by 30-50 per cent annually."
The market for nutraceutical ingredients with a health-promoting effect is estimated to have a value of around USD 8bn and is forecast to double by 2015. Resveratrol is thought to have blockbuster potential, which means sales exceeding USD 1bn.
Fluxome Sciences' technology platform involves metabolic engineering that converts microorganisms such as yeast into 'cell factories' that can be designed to produce specific chemical compounds, such as resveratrol, via fermentation.
Fluxome Sciences was founded in 2002 as a spin-out from the Technical University of Denmark. The company has just moved its headquarters to Stenlose, which is located about 30 km from Copenhagen.